"rationale","id","instanceType","versionIdentifier","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","StudyVersion","2","b8c45341-bfc5-4058-b211-9ee13800b8af"
